Stock ACUR ACURA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Acura Pharmaceuticals, Inc.

Equities

ACUR

US00509L8028

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 01:09:25 04/05/2024 am IST 		5-day change 1st Jan Change
0.0041 USD +36.67% Intraday chart for Acura Pharmaceuticals, Inc. 0.00% +4,000.00%
26/03 Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC CI
14/03 Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 9.071 8.399 2.417 4.899 4.547 32.54
Enterprise Value (EV) 1 11.74 8.873 6.55 10.04 10.4 32.68
P/E ratio -1.23 x -1.12 x -0.63 x -1.63 x -5.25 x -25 x
Yield - - - - - -
Capitalization / Revenue 2.03 x 2.83 x 5.89 x 1.84 x 1.27 x 20.8 x
EV / Revenue 2.63 x 2.99 x 16 x 3.78 x 2.91 x 20.9 x
EV / EBITDA -1.89 x -1.8 x -1.8 x -22.2 x 297 x -28.6 x
EV / FCF -3.48 x 9.21 x -2.5 x -17.6 x -32 x -29.7 x
FCF Yield -28.7% 10.9% -40% -5.7% -3.13% -3.37%
Price to Book 7.67 x -311 x -0.67 x -1.03 x -0.77 x 183 x
Nbr of stocks (in thousands) 11,834 20,796 21,034 21,300 21,650 65,089
Reference price 2 0.7665 0.4039 0.1149 0.2300 0.2100 0.5000
Announcement Date 31/03/17 07/06/18 16/09/19 31/03/20 31/03/21 30/06/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 4.464 2.966 0.41 2.657 3.57 1.563
EBITDA 1 -6.212 -4.931 -3.635 -0.452 0.035 -1.141
EBIT 1 -6.557 -5.225 -3.915 -0.725 -0.09 -1.214
Operating Margin -146.89% -176.16% -954.88% -27.29% -2.52% -77.67%
Earnings before Tax (EBT) 1 -7.388 -5.817 -3.842 -3.774 -1.208 -0.879
Net income 1 -7.388 -5.682 -3.842 -3.774 -1.208 -0.879
Net margin -165.5% -191.57% -937.07% -142.04% -33.84% -56.24%
EPS 2 -0.6224 -0.3600 -0.1817 -0.1412 -0.0400 -0.0200
Free Cash Flow 1 -3.374 0.9639 -2.623 -0.5719 -0.3255 -1.101
FCF margin -75.59% 32.5% -639.7% -21.52% -9.12% -70.43%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 31/03/17 07/06/18 16/09/19 31/03/20 31/03/21 30/06/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 2.67 0.47 4.13 5.14 5.86 0.14
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.4305 x -0.0961 x -1.137 x -11.37 x 167.3 x -0.1183 x
Free Cash Flow 1 -3.37 0.96 -2.62 -0.57 -0.33 -1.1
ROE (net income / shareholders' equity) -163% -983% 211% 90.3% 22.7% 30.8%
ROA (Net income/ Total Assets) -32.6% -51% -72.4% -19.2% -2.62% -58.5%
Assets 1 22.69 11.15 5.304 19.63 46.15 1.504
Book Value Per Share 2 0.1000 -0 -0.1700 -0.2200 -0.2700 0
Cash Flow per Share 2 0.2300 0.1100 0 0.0400 0.0200 0
Capex 1 0.08 - - - - -
Capex / Sales 1.68% - - - - -
Announcement Date 31/03/17 07/06/18 16/09/19 31/03/20 31/03/21 30/06/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACURA PHARMACEUTICALS, INC. Stock Acura Pharmaceuticals, Inc.
+4,000.00% 3L
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 11TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 11TCr
ARGENX SE Stock argenx SE
+1.05% 2.23TCr
BIONTECH SE Stock BioNTech SE
-12.64% 2.22TCr
GENMAB A/S Stock Genmab A/S
-5.15% 1.94TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 1.79TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 1.72TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.77% 1.43TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 1.25TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ACUR Stock
  4. Financials Acura Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW